Renouf, D. J., Topham, J. T., Loree, J. M., Tu, D., Schaeffer, D. F., Knox, J. J., Kavan, P., Jonker, D. J., Welch, S., Couture, F., Lemay, F., Tehfe, M., Harb, M., Aucoin, N., Ko, Y., Tang, P. A., Du, P., Jia, S., Gill, S., O'Callaghan, C. J. (2025). Concurrent mutations in DNA damage repair genes
            <i>BRCA1</i>
            ,
            <i>POLE</i>
            ,
            <i>ATM</i>
            and
            <i>FANCA</i>
            to predict overall and progression-free survival for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with chemotherapy in combination with dual checkpoint inhibition in the CCTG randomized PA.7 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4178